Back to search results

Improving HIV and Hepatitis C Testing in Opioid Treatment Programs

This study, called Project I Test, is looking at ways to improve how opioid treatment programs (OTPs) offer HIV and Hepatitis C (HCV) testing to their patients. Researchers are testing two different "practice coaching" interventions. These interventions provide support and guidance to OTP staff to help them offer more on-site HIV and HIV/HCV testing and connect patients to care if they test positive. The study aims to see how well these coaching methods increase the number of patients who get tested for HIV. You might be able to join if you are an adult (18 years or older) and are a patient at an OTP that is participating in the study. The study is currently unclear about its recruitment status.

Study design
This interventional study will randomly assign 51 opioid treatment programs to one of three groups, with 17 sites per group, to compare different approaches to HIV and HCV testing.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure the proportion of patients tested for HIV at 6 months after the intervention or control period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03135886

Project I Test: Implementing HIV Testing in Opioid Treatment Programs

Recruiting
NAAges 18+InterventionalHealth services
Columbia University
~418 participants
Updated 2026-08-07 on ClinicalTrials.gov
What's tested:Information ControlHIV and HCV Testing Practice Coaching InterventionHIV Testing Practice Coaching Intervention

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of OTP patients HIV tested at 6 months post intervention or control, while controlling for HIV testing during the baseline period (T1)
Measured over The period 7-12 months post site-randomization (T3).

Conditions

HIV/AIDS
Hepatitis C
Substance Use Disorders
Opioid-use Disorder

Explore related trials

Hepatitis C InfectionHIV InfectionOpioid Use Disorder

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Lisa Metsch, PhD · PRINCIPAL_INVESTIGATOR · Columbia University
  • Daniel Feaster, PhD · PRINCIPAL_INVESTIGATOR · University of Miami
  • Jemima Frimpong, PhD · PRINCIPAL_INVESTIGATOR · New York University Abu Dhabi
  • Lauren Gooden, PhD · STUDY_DIRECTOR · Columbia University

Who to contact

Lauren Gooden, PhD
[email protected]
786-703-9819
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Eligible sites must:

Exclusion

Sites will be excluded if:

What this trial measures

  • Proportion of OTP patients HIV tested at 6 months post intervention or control, while controlling for HIV testing during the baseline period (T1)The period 7-12 months post site-randomization (T3).

    The primary outcome measure will be a contrast of the proportion of OTP patients HIV tested during T3, controlling for HIV testing at baseline (T1). The primary test will be whether the proportion of patients tested across the two PC interventions--HIV Testing PC Intervention Group and HIV/HCV Testing PC Intervention Group--differs from the proportion of patients tested in the Information Control Group.